特一藥業(002728.SZ):當前的中藥材升價對公司的經營影響較小
格隆匯8月16日丨有投資者向特一藥業(002728.SZ)提問,“中藥材大幅升價,對貴公司的經營有什麼影響?”,公司回覆稱,公司核心產品止咳寶片的主要原材料是由罌粟殼提取的浸膏,公司採購的罌粟殼是根據國家藥監部門批覆的採購申請,到國家指定的甘肅農墾進行採購,該價格為國家發改委定價,調整幅度較小;公司採購的其他中藥材,總體看,採購成本呈上升的趨勢,但公司一般根據市場需求、原材料供需情況,制定原材料採購計劃,在保證供貨質量的情況下,實行經濟批量進貨,控制採購成本。此外,公司配備專門的中藥材倉庫,公司可根據後續的市場需求作充分的安全儲備。當前的中藥材升價對公司的經營影響較小。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.